Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy

Biochim Biophys Acta Mol Basis Dis. 2023 Sep 9:166881. doi: 10.1016/j.bbadis.2023.166881. Online ahead of print.ABSTRACTGastric cancer (GC) is an increasing global health problem and is one of the leading cancers worldwide. Traditional therapies, such as radiation and chemotherapy, have made limited progress in enhancing their efficacy for advanced GC. The development of immunotherapy for advanced GC has considerably improved with a deeper understanding of the tumor microenvironment. Immunotherapy using checkpoint inhibitors is a new therapeutic option that has made substantial advances in the treatment of other malignancies and is increasingly used in other clinical oncology treatments. Particularly, therapeutic antibodies targeting the programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have been effectively used in the clinical treatment of cancer. Monoclonal antibodies blocking the PD-1/PD-L1 pathway have been developed for cancer immunotherapy to enhance T cell function to restore the immune response and represent a breakthrough in the treatment of GC. This review provides an outline of the progress of PD-1/PD-L1 blockade therapy and its expression characteristics and clinical application in advanced GC.PMID:37696462 | DOI:10.1016/j.bbadis.2023.166881
Source: Biochimica et Biophysica Acta - Category: Biochemistry Authors: Source Type: research